参考文献
［1］中华医学会糖尿病学分会.中国2型糖尿病防治指南（2020年版）[J].中华糖尿病杂志，2021.13（4）： 315-409.
［2］Lindström J,Ilanne-Parikka P,Peltonen M,et al.Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study[J].Lancet,2006,368(9548): 1673-1679.
［3］Li G,Zhang P,Wang J,et al.The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study[J].Lancet,2008.371(9626): 1783-1789.
［4］Knowler WC,Fowler SE,Hamman RF,et al.10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study[J].Lancet.2009,374(9702): 1677-1686.
［5］Holman RR,Coleman RL,Chan J,et al.Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised,double-blind,placebo-controlled trial[J].Lancet Diabetes Endocrinol,2017,5(11): 877-886.
［6］DeFronzo RA,Tripathy D,Schwenke DC,et al.Pioglitazone for diabetes prevention in impaired glucose tolerance[J].N Engl J Med,2011,364(12): 1104-1115.
［7］Torgerson JS,Hauptman J,Boldrin MN,et al.XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients[J].Diabetes Care,2004,27(1): 155-161.
［8］中华人民共和国卫生行业标准 糖尿病筛查和诊断[J].实用防盲技术，2012，7（4）： 180-184.
［9］Zhou X,Qiao Q,Ji L,et al.Nonlaboratory-based risk assessment algorithm for undiagnosed type 2 diabetes developed on a nation-wide diabetes survey.Diabetes Care,2013,36(12): 3944-3952.
［10］Stratton IM,Adler AI,Neil HA,et al.Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35):prospective observational study[J].BMJ,2000,321(7258): 405-412.
［11］Holman RR,Paul SK,Bethel MA,,et al.10-year follow-up of intensive glucose control in type 2 diabetes[J].N Engl J Med,2008,359(15): 1577-1589.
［12］Hirst JA,Farmer AJ,Dyar A,,et al.Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis[J].Diabetologia,2013,56(5):973-984.
［13］Landgraf R.Meglitinide analogues in the treatment of type 2 diabetes mellitus[J].Drugs Aging,2000,17(5): 411-425.
［14］潘长玉，高妍，高鑫等.盐酸吡格列酮治疗2型糖尿病的有效性和安全性的多中心临床研究[J].中华内科杂志，2002（6）： 31-35.
［15］Pan C,Han P,Ji Q,et al.Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China,Taiwan,and Hong Kong[J].J Diabetes,2017,9(4): 386-395.
［16］Ba J,Han P,Yuan G,et al.Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin[J].J Diabetes.2017.9(7): 667-676.
［17］White WB,Cannon CP,Heller SR,et al.Alogliptin after acute coronary syndrome in patients with type 2 diabetes[J].N Engl J Med,2013,369(14): 1327-1335.
［18］Rosenstock J,Perkovic V,Johansen OE,et al.Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial[J].JAMA,2019,321(1): 69-79.(https://www.daowen.com)
［19］陆菊明.基于胰高血糖素样肽1降糖药物的临床应用共识[J].中华糖尿病杂志，2014，6（1）： 14-20.
［20］Group U.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34)[J].Lancet,1998,352(9131): 854-865.
［21］Kooy A,de Jager J,Lehert P,et al.Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus[J].Arch Intern Med,2009,169(6): 616-625.
［22］Kristensen S L,Rørth R,Jhund P S,et al.Cardiovascular,mortality,and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J].Lancet Diabetes Endocrinol,2019,7(10): 776-785.
［23］Gerstein HC,Colhoun HM,Dagenais GR,et al.Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind,randomised placebo-controlled trial[J].Lancet,2019,394(10193): 121-130.
［24］Hernandez AF,Green JB,Janmohamed S,et al.Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease(Harmony Outcomes): a double-blind,randomised placebo-controlled trial[J].Lancet,2018,392(10157): 1519-1529.
［25］Neal B,Perkovic V,Mahaffey KW,et al.Canagliflozin,and Cardiovascular and Renal Events in Type 2 Diabetes[J].N Engl J Med,2017,377(7): 644-657.
［26］Wiviott SD,Raz I,Bonaca MP,et al.Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes[J].N Engl J Med,2019,380(4): 347-357.
［27］Cannon CP,Pratley R,Dagogo-Jack S,et al.Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes[J].N Engl J Med,2020,383(15): 1425-1435.
［28］Group U.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38[J].Bmj British Medical Journal,1998,317(7160):703-713.
［29］Snow V,Weiss KB,Mottur-Pilson C.The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus[J].Ann Intern Med,2003,138(7): 587-592.
［30］Colhoun HM,Betteridge DJ,Durrington PN,et al.Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial[J].Lancet,2004,364(9435): 685-96.
［31］Gerstein HC,Miller ME,Byington RP,et al.Effects of intensive glucose lowering in type 2 diabetes[J].N Engl J Med,2008,358(24): 2545-2559.
［32］Gaede P,Lund-Andersen H,Parving HH,et al.Effect of a multifactorial intervention on mortality in type 2 diabetes[J].N Engl J Med.2008.358(6): 580-91.
［33］Vaag AA.Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study[J].Endocr Pract,2006,12(1): 89-92.
［34］McMurray J,Solomon SD,Inzucchi SE,et al.Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction[J].N Engl J Med,2019,381(21): 1995-2008.
［35］Packer M,Anker S D,Butler J,et al.Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial[J].Circulation,2021,143(4): 326-336.
（朱凌燕、梅洵、张钰英）